TORRENT-LEVETIRACETAM TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
30-01-2015
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
LEVETIRACETAM
Tilgjengelig fra:
TORRENT PHARMACEUTICALS LIMITED
ATC-kode:
N03AX14
INN (International Name):
LEVETIRACETAM
Dosering :
750MG
Legemiddelform:
TABLET
Sammensetning:
LEVETIRACETAM 750MG
Administreringsrute:
ORAL
Enheter i pakken:
100/120
Resept typen:
Prescription
Terapeutisk område:
MISCELLANEOUS ANTICONVULSANTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0148843003; AHFS:
Autorisasjon status:
CANCELLED (UNRETURNED ANNUAL)
Autorisasjon dato:
2021-12-20
Preparatomtale
_ _
_ _
_Page 1 of 32_
PRODUCT MONOGRAPH
PR
TORRENT-LEVETIRACETAM
Levetiracetam Tablets USP
250 mg, 500 mg and 750 mg
Antiepileptic Agent
Torrent Pharmaceuticals Ltd.
Indrad – 382 721,
Dist. Mehsana
India
Control # 181391
Date of Revision:
January 26, 2015
_ _
_ _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
..........................................................................................................20
DETAILED PHARMACOLOGY
..........................................................................
Les hele dokumentet
